In patient-derived xenograft (PDX) mouse tumor models, we found that TPX2 overexpression increased the antitumor activity of CD8+ T cells, enhanced the response to anti-PD-1 therapy, and dramatically inhibited tumor growth, but TPX2 knockdown promoted tumor growth and compromised the antitumor efficiency of CD8 + T cells. This evidence concerns the gene CD8A and neoplasm.